This study demonstrated the promise of using a TLR4 inhibitor such as resatorvid for HCC chemoprevention and suggested that patients with obesity, diabetes and/or NAFLD should be the target population for this chemoprevention approach. The gene discussed is TLR4; the disease is metabolic dysfunction-associated steatotic liver disease.